Oppenheimer Initiates Coverage On Acrivon Therapeutics with Outperform Rating, Announces Price Target of $25
Portfolio Pulse from richadhand@benzinga.com
Oppenheimer analyst Matthew Biegler initiates coverage on Acrivon Therapeutics (NASDAQ:ACRV) with an Outperform rating and a price target of $25.
June 02, 2023 | 8:35 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oppenheimer initiates coverage on Acrivon Therapeutics with an Outperform rating and a price target of $25.
The initiation of coverage by Oppenheimer with an Outperform rating and a price target of $25 indicates a positive outlook for Acrivon Therapeutics. This news is likely to attract investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100